logo

Arbutus Biopharma Corp. (ABUS)



Trade ABUS now with
  Date
  Headline
11/26/2018 4:53:32 PM Arbutus Appoints Frank Torti As Chairman Of Its Board Of Directors
10/15/2018 6:29:05 AM Wedbush Lifts Arbutus Biopharma Corp. (ABUS) To Neutral From Underperform With $ Price Target
10/9/2018 4:53:34 PM Wedbush Lowers Arbutus Biopharma Corp. (ABUS) To Underperform From Neutral With $5 Down From $7 Price Target
8/13/2018 8:32:39 AM Arbutus’ LNP Licensee Alnylam Announces FDA Approval Of ONPATTRO For ATTR Amyloidosis
8/13/2018 7:17:34 AM Wedbush Is Increasing Arbutus Biopharma Corp. (ABUS) FY18 Rev. Estimate To 3.1 M From 1.4 M
8/13/2018 7:17:17 AM Wedbush Is Increasing Arbutus Biopharma Corp. (ABUS) FY18 Estimate To -1.09 From -1.40
8/13/2018 7:16:50 AM Wedbush Is Cutting Arbutus Biopharma Corp. (ABUS) Q4 18 Estimate To -0.37 From -0.34
8/13/2018 7:16:42 AM Wedbush Is Lowering Arbutus Biopharma Corp. (ABUS) Q3 18 Estimate To -0.37 From -0.33
3/19/2018 1:34:51 PM Wedbush Is Raising Arbutus Biopharma Corp. (ABUS) 2018 Estimate To -1.33 From -1.54
3/19/2018 1:34:37 PM Wedbush Is Increasing Arbutus Biopharma Corp. (ABUS) 4Q18 Estimate To -0.34 From -0.40
3/19/2018 1:34:20 PM Wedbush Is Raising Arbutus Biopharma Corp. (ABUS) 3Q18 Estimate To -0.34 From -0.39
3/19/2018 1:33:55 PM Wedbush Is Increasing Arbutus Biopharma Corp. (ABUS) 2Q18 Estimate To -0.33 From -0.38
3/19/2018 1:33:39 PM Wedbush Is Increasing Arbutus Biopharma Corp. (ABUS) 1Q18 Estimate To -0.32 From -0.37
3/19/2018 9:30:05 AM Wedbush Downgrades Arbutus Biopharma Corp. (ABUS) To Neutral From Outperform With $6 Down From $9 Price Target
2/22/2018 4:57:08 PM Arbutus Biopharma Settles Litigation; Acuitas Has No Further Rights To Use Or Sublicense Arbutus LNP Technology